[Non-revascularisation of acute coronary syndrome with ST elevation].
National therapeutic strategies in acute coronary syndromes (ACS) required revaluation, especially with regards to reperfusion. RICO is an observatory of ACS in the Côte d'Or district. Between January 1st 2001 and April 31st 2003, the cases of 706 patients with ACS and persistent ST elevation or appearances of left bundle branch block eligible for revascularisation (admitted < 12 hours after onset of symptoms and no contra-indications to thrombolysis), were reviewed. The number of revascularised patients was 488 (69%) and 218 (31%) were not revascularised. Thrombolysis was the most commonly used method of revascularisation (66%) in this district: 34% underwent primary angioplasty. Multivariate analysis showed only three independent predictive factors of non-reperfusion during the acute phase. They were: age (> or = 75 years) (p < 0.001), left bundle branch block (p = 0.002) and hospital admission > or = 6 hours after onset of symptoms (p < 0.001). These results confirm the utility of developing networks to improve the efficacy of management and reduce the delay before hospital admission. They also identify specific population groups, the elderly for example, who require specific therapeutic strategies for coronary revascularisation in ACS.
Zeller
M
M
Service de cardiologie, CHU Bocage, Dijon.
Dentan
G
G
Hamou
K Hadj
KH
Beer
J C
JC
L'Huillier
I
I
Janin-Manificat
L
L
Makki
H
H
Laurent
Y
Y
Louis
P
P
Cottin
Y
Y
Wolf
J E
JE
D000208:Acute Disease; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data; D002037:Bundle-Branch Block / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D015897:Comorbidity; D000075202:Contraindications; D003327:Coronary Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy; D042241:Early Diagnosis; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006760:Hospitalization; D006801:Humans; D008297:Male; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D011159:Population Surveillance; D011446:Prospective Studies; D012307:Risk Factors; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents